Skip to main content

Table 3 Univariate analysis evaluating the factors associated with increase(s) in cisatracurium dosage

From: How to reduce cisatracurium consumption in ARDS patients: the TOF-ARDS study

Variables No cisatracurium dosage increase N = 18 Cisatracurium dosage increases N = 12 p value
Age, years 64 (47–70) 63 (53–76) 0.54
Female, n (%) 5 (28) 2 (17) 0.67
Height, cms 170 (160–175) 170 (161–174) 0.66
Weight, kgs 74 (59–86) 82 (68–110) 0.14
SAPS 2 47 (28–54) 44 (41–53) 0.78
SOFA 8 (7–12) 8 (7–10) 0.37
Characteristics at day 1    
Vt, mL 410 (380–420) 390 (360–437) 0.60
Vt, mL/kg (PBW) 6.2 (5.6–6.8) 6.2 (5.4–6.78) 0.85
Respiratory rate 26 (22–28) 24 (20–27) 0.25
PEEP, cm H20 12 (10–14) 8 (8–11.5) 0.008
Pplat, cm H20 25 (22–26) 25 (22–27) 0.92
Driving pressure, cm H2O 12 (10–15) 15 (13–16) 0.017
PaO2/FiO2 ratio 92 (70–119) 107 (100–121) 0.14
Severe versus moderate ARDS, n (%) 10 (55) 3 (25) 0.14
pH 7.32 (7.22–7.36) 7.33 (7.30–7.42) 0.49
PaCO2, mmHg 47 (39–57) 44 (41–57) 0.92
Prone position, n (%) 10 (55) 3 (25) 0.14
Bicarbonates, mmol/L 24 (21–29) 27 (24–32) 0.15
Lactate, mmol/L 1.28 (1.10–1.91) 1.27 (0.97–2.22) 0.87
Vasopressor use, n (%) 17 (94) 10 (83) 0.55
Norepinephrine, mg/h 1.1 (0.55–2.5) 1 (0.0–1.7) 0.32
Body temperature, °C 38.1 (37.5–38.6) 38.1 (37.4–38.6) 0.95
Ketamine use, n (%) 5 (28) 4 (33) 1
Other organ failure, (n 0/1/2/>2) 1/13/4/0 3/4/4/1 0.12
  1. Variables are presented as the median ± interquartile range. ARDS acute respiratory distress syndrome, PBW predicted body weight, PEEP positive end-expiratory pressure, Pplat, end-inspiratory plateau pressure, SAPS 2 Simplified Acute Severity Score 2, SOFA, Sepsis-related Organ Failure Assessment, Vt tidal volume, ARDS acute respiratory distress syndrome, PEEP, positive end-expiratory pressure